EndotoxemiaNCT05752968
Elevated Levels of Antibodies to Endotoxin Core in Hemodialysis Patients With Peripheral Artery Disease
An observational study of Endotoxemia and Peripheral Arterial Disease, run by Tungs' Taichung Metroharbour Hospital at 1 site in Taiwan.
Trial summary
Background Peripheral arterial disease (PAD) and its relevant complications are more common in hemodialysis (HD) patients. The potential association regarding chronic kidney disease dysbiosis, inflammation and metabolic endotoxinemia in HD patients is unknown. Read more about this study
- Who is it for?
- Ages 20 years and older
- Conditions the study is for
- Endotoxemia, Peripheral Arterial Disease
- How many people
- 155 participants
- Where
- 1 siteTaiwan
- Study dates
- 3 May 2023to 31 Dec 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: patients have to be at least 20-years-old and hemodialysis (HD) for at least 1 months.
Who may be able to join
- A cohort of aged 20 or over, who receive hemodialysis with ultrapure dialysate three times weekly for at least 1 month.
Who cannot join
- We will exclude patients dialyzed with a catheter; who had an acute infection requiring hospitalization; and who had underlying malignancy or autoimmune diseases. In addition, patients who refuse to participate will be excluded.
Trial locations and contacts
1 site in 1 country.
About this study
Background
Peripheral arterial disease (PAD) and its relevant complications are more common in hemodialysis (HD) patients. The potential association regarding chronic kidney disease dysbiosis, inflammation and metabolic endotoxinemia in HD patients is unknown. A cross-sectional study will be carried out the evaluate the possible association endotoxin core antibody with asymptomatic PAD in a cohort of HD patients.
Read more
Methods
This cohort study enrolled 500 HD patients treated at a single center in Taichung city. Fasting blood samples will be collected to determine biochemical data Endotoxin core antibody levels and other related biomarkers. By the automatic oscillometric method, the ankle-brachial index (ABI) was measured. Low ABI was defined as any value < 0.9.
Read the detailed description
Study Design and Patients This is a cross-sectional study involving hemodialysis patients from the hemodialysis unit of Tungs' Taichung MetroHarbor Hospital, Taiwan. A total of 500 patients over 20 years of age who receive hemodialysis with ultrapure dialysate three times weekly for at least 1 month are eligible for enrollment. We will exclude patients dialyzed with a catheter; who had an acute infection requiring hospitalization; and who had underlying malignancy or autoimmune diseases. In addition, patients who refuse to participate will be excluded. Information on participant demographics and comorbidities will be obtained from interviews and medical record reviews at the time of enrollment. Diabetes mellitus is defined by self-reported history or use of antidiabetic medications. Hypertension was defined as systolic blood pressure ≥140 mmHg, diastolic ≥90 mmHg, or use of antihypertensive agents. Pre-exisiting CVD is defined as coronary artery disease, as documented by coronary angiography or a history of myocardial infarction, class III or IV congestive heart failure, or stroke. This study will comply with the Declaration of Helsinki and will apply for approval from the Institutional Review Board of Tungs' Taichung MetroHarbor Hospital. All participants will give their written informed consent.
Laboratory Measurements Predialysis blood samples are obtained on a mid-week day. Within 30 min after sampling, the remaining blood will be centrifuged at 3,000 g for 10 min, immediately aliquoted and frozen at-70 °C until further analysis. The total serum cholesterol is measured through the reaction of cholesterol esterase/cholesterol oxidase/ peroxidase, using Hitachi 747 (Hitachi, Bohemia, NY, USA). HDL cholesterol is quantified after precipitation with polyethylene glycol at room temperature. Serum glucose concentrations are measured by the glucose oxidase method. Low-density lipoprotein cholesterol is calculated using the Friedewald formula. Total serum triglycerides are measured through the reaction of glycerol/ phosphate/oxidase and peroxidase. The serum levels of high-sensitivity C-reactive protein (hsCRP) are measured using a Behring Nephelometer II (Dade Behring, Tokyo, Japan). Serum levels of IL-6 and sCD14 are measured by a commercially available enzyme-linked immunosorbent assay (Quantikine HS Immunoassay kit, R\&D System, Minneapolis, MN, USA). The LBP will be determined from serum samples and controls using standardized enzyme-linked immunosorbent assay methods (HK315-02, HyCult Biotech Inc., Uden, The Netherlands), and serum from 20 normal control subjects are used for interassay variation. Serum endotoxin core antibody will be tested using a commercially available EndoCab IgG ELISA assay (Hycult Biotech Inc., The Netherlands). In addition, serum LCN-2 (Lipocalin-2) and YKL-40 concentrations will be determined using enzyme linked immunosorbent assays
Endotoxin Measurement Endotoxin levels are measured using a Charles River Laboratories (CRL) Kinetic Chromogenic assay, Endochrome-K. A more detailed description of the methodology used has been described elsewhere [37]. Samples are thawed and diluted to 1 : 20 with a bio-dispersing agent (CRL, BD100) and heat to 75°C for 15 minutes. A standard curve (0.005 EU/mL and 5 EU/mL) is prepared using control standard endotoxin supplied by CRL. If endotoxin is detected, the samples are then reconstituted with an endotoxin-specific buffer (Charles River Endosafe BG-120) to avoid any β-glucan-related false positive reaction. A positive product control is included for each sample to eliminate the possibility of enhancement or inhibition of endotoxin measurement. The absorbance at 405 nm is measured at 30 second intervals for a total of 3600 seconds using a Biotek ELx808 plate reader. The assay reactions are held at 37°C throughout the assay period. Charles River Endosafe, EndoScan V software is used to generate a standard curve and analyze data using an onset time of 0.1 absorbance unit.
- Conditions
- Endotoxemia, Peripheral Arterial Disease
- Keywords
- Peripheral Arterial Disease, Endotoxin core antibody
- Medical subject headings
- Endotoxemia, Peripheral Arterial Disease
What is being measured
The primary outcome is the main question the study is designed to answer.
Analysis of biomarkers of endotoxin core antibody (EndoCab) levels
Plasma level of endotoxin core antibody (EndoCab) is a biomarkers for the risk of developing and presence of PAD
Measured: 1 years
Secondary outcomes (5)
Ankle Brachial Index Measurements
Diagnostic criterion for asymptomatic PAD
Measured: 1 years
Analysis of biomarkers of IL-6
The IL-6 was determined from plasma samples using standardized enzymelinked immunosorbent assay (ELISA) methods
Measured: 1 years
Analysis of biomarkers of sCD14
The sCD14 was determined from plasma samples using standardized enzymelinked immunosorbent assay (ELISA) methods assay (ELISA) methods
Measured: 1 years
Analysis of biomarkers of LCN-2 (Lipocalin-2)
The LCN-2 (Lipocalin-2) was determined from plasma samples using standardized enzymelinked immunosorbent assay (ELISA) methods
Measured: 1 years
Analysis of biomarkers of YKL-40
The YKL-40 was determined from plasma samples using standardized enzymelinked immunosorbent assay (ELISA) methods
Measured: 1 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Mar 2023
- Study start3 May 2023
- Primary completion31 Dec 2023
- Study completion31 Dec 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for EndotoxemiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 155 participants (actual)
Sponsor and investigators
- Lead sponsor
- Tungs' Taichung Metroharbour Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Paik Seong Lim, PhD, Principal investigator, Tungs' Taichung Metroharbour Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05752968
- Sponsor's protocol ID
- 111064
- Status last verified
- Feb 2024
- First submitted
- 21 Feb 2023
- Last updated
- 1 Mar 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Mar 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Elevated Levels of Antibodies to Endotoxin Core in Hemodialysis Patients With Peripheral Artery Disease
- ClinicalTrials.gov ID
- NCT05752968
- Acronym / sponsor ID
- 111064
- Conditions
- Endotoxemia, Peripheral Arterial Disease
- Keywords
- Peripheral Arterial Disease, Endotoxin core antibody
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 155 participants (actual)
- Lead sponsor
- Tungs' Taichung Metroharbour HospitalUniversity, hospital or other
- Study start
- 3 May 2023 (actual)
- Primary completion
- 31 Dec 2023 (actual)
- Study completion
- 31 Dec 2023 (actual)
- First posted
- 3 Mar 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background
Peripheral arterial disease (PAD) and its relevant complications are more common in hemodialysis (HD) patients. The potential association regarding chronic kidney disease dysbiosis, inflammation and metabolic endotoxinemia in HD patients is unknown. A cross-sectional study will be carried out the evaluate the possible association endotoxin core antibody with asymptomatic PAD in a cohort of HD patients.
Methods
This cohort study enrolled 500 HD patients treated at a single center in Taichung city. Fasting blood samples will be collected to determine biochemical data Endotoxin core antibody levels and other related biomarkers. By the automatic oscillometric method, the ankle-brachial index (ABI) was measured. Low ABI was defined as any value < 0.9.
Detailed description
Study Design and Patients This is a cross-sectional study involving hemodialysis patients from the hemodialysis unit of Tungs' Taichung MetroHarbor Hospital, Taiwan. A total of 500 patients over 20 years of age who receive hemodialysis with ultrapure dialysate three times weekly for at least 1 month are eligible for enrollment. We will exclude patients dialyzed with a catheter; who had an acute infection requiring hospitalization; and who had underlying malignancy or autoimmune diseases. In addition, patients who refuse to participate will be excluded. Information on participant demographics and comorbidities will be obtained from interviews and medical record reviews at the time of enrollment. Diabetes mellitus is defined by self-reported history or use of antidiabetic medications. Hypertension was defined as systolic blood pressure ≥140 mmHg, diastolic ≥90 mmHg, or use of antihypertensive agents. Pre-exisiting CVD is defined as coronary artery disease, as documented by coronary angiography or a history of myocardial infarction, class III or IV congestive heart failure, or stroke. This study will comply with the Declaration of Helsinki and will apply for approval from the Institutional Review Board of Tungs' Taichung MetroHarbor Hospital. All participants will give their written informed consent.
Laboratory Measurements Predialysis blood samples are obtained on a mid-week day. Within 30 min after sampling, the remaining blood will be centrifuged at 3,000 g for 10 min, immediately aliquoted and frozen at-70 °C until further analysis. The total serum cholesterol is measured through the reaction of cholesterol esterase/cholesterol oxidase/ peroxidase, using Hitachi 747 (Hitachi, Bohemia, NY, USA). HDL cholesterol is quantified after precipitation with polyethylene glycol at room temperature. Serum glucose concentrations are measured by the glucose oxidase method. Low-density lipoprotein cholesterol is calculated using the Friedewald formula. Total serum triglycerides are measured through the reaction of glycerol/ phosphate/oxidase and peroxidase. The serum levels of high-sensitivity C-reactive protein (hsCRP) are measured using a Behring Nephelometer II (Dade Behring, Tokyo, Japan). Serum levels of IL-6 and sCD14 are measured by a commercially available enzyme-linked immunosorbent assay (Quantikine HS Immunoassay kit, R\&D System, Minneapolis, MN, USA). The LBP will be determined from serum samples and controls using standardized enzyme-linked immunosorbent assay methods (HK315-02, HyCult Biotech Inc., Uden, The Netherlands), and serum from 20 normal control subjects are used for interassay variation. Serum endotoxin core antibody will be tested using a commercially available EndoCab IgG ELISA assay (Hycult Biotech Inc., The Netherlands). In addition, serum LCN-2 (Lipocalin-2) and YKL-40 concentrations will be determined using enzyme linked immunosorbent assays
Endotoxin Measurement Endotoxin levels are measured using a Charles River Laboratories (CRL) Kinetic Chromogenic assay, Endochrome-K. A more detailed description of the methodology used has been described elsewhere [37]. Samples are thawed and diluted to 1 : 20 with a bio-dispersing agent (CRL, BD100) and heat to 75°C for 15 minutes. A standard curve (0.005 EU/mL and 5 EU/mL) is prepared using control standard endotoxin supplied by CRL. If endotoxin is detected, the samples are then reconstituted with an endotoxin-specific buffer (Charles River Endosafe BG-120) to avoid any β-glucan-related false positive reaction. A positive product control is included for each sample to eliminate the possibility of enhancement or inhibition of endotoxin measurement. The absorbance at 405 nm is measured at 30 second intervals for a total of 3600 seconds using a Biotek ELx808 plate reader. The assay reactions are held at 37°C throughout the assay period. Charles River Endosafe, EndoScan V software is used to generate a standard curve and analyze data using an onset time of 0.1 absorbance unit.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 20 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- patients have to be at least 20-years-old and hemodialysis (HD) for at least 1 months.
Key inclusion criteria (1 listed)
- A cohort of aged 20 or over, who receive hemodialysis with ultrapure dialysate three times weekly for at least 1 month.
Key exclusion criteria (1 listed)
- We will exclude patients dialyzed with a catheter; who had an acute infection requiring hospitalization; and who had underlying malignancy or autoimmune diseases. In addition, patients who refuse to participate will be excluded.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Analysis of biomarkers of endotoxin core antibody (EndoCab) levels
Time frame: 1 years
Plasma level of endotoxin core antibody (EndoCab) is a biomarkers for the risk of developing and presence of PAD
5 secondary outcomes
Ankle Brachial Index Measurements
Time frame: 1 years
Analysis of biomarkers of IL-6
Time frame: 1 years
Analysis of biomarkers of sCD14
Time frame: 1 years
Analysis of biomarkers of LCN-2 (Lipocalin-2)
Time frame: 1 years
Analysis of biomarkers of YKL-40
Time frame: 1 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Mar 2024.
Related trials for Endotoxemia
Recruiting
Short-Chain Fatty Acids in Lypopolysaccharide-Induced Inflammation and Executive Function
Endotoxemia, Inflammation
Not yet recruiting
Hemoadsorpion in Patients With Septic Shock: Efficacy and Safety Evaluation
Septic Shock
Not yet recruitingObservational study
Intestinal Endotoxemia and Beta- Cell Dysfunction in Prediabetics
Prediabetic State (IGT), Prediabetic State
RecruitingObservational study
OxiCLEAR (Oxiris Cytokines and Endotoxin Adsorption Rate) Study
Sepsis, Septic Shock
Active, not recruiting
Assessing Gut Microbiota Mediated Health Outcomes of Whole Wheat and Its Major Bioactive Components
PreDiabetes, Dysbiosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Paik Seong Lim, PhD principal investigator
Tungs' Taichung Metroharbour Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Endotoxemia and Peripheral Arterial Disease, run by Tungs' Taichung Metroharbour Hospital at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Mar 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Analysis of biomarkers of endotoxin core antibody (EndoCab) levels (time frame: 1 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Mar 2024.